Discovery of benzo[cd]indol-2-one and benzylidene-thiazolidine-2,4-dione as new classes of NLRP3 inflammasome inhibitors via ER-β structure based virtual screening
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 95, 103500
Abstract
No abstract availableKeywords
Funding Information
- CSIR YSA (P90807)
- CSIR (MLP-5005)
This publication has 28 references indexed in Scilit:
- Inhibiting the Inflammasome: A Chemical PerspectiveJournal of Medicinal Chemistry, 2015
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseasesNature Medicine, 2015
- Retinoic acid as a therapeutic option in Alzheimer’s disease: a focus on cholinergic restorationExpert Review of Neurotherapeutics, 2015
- Heterogeneity of CNS myeloid cells and their roles in neurodegenerationNature Neuroscience, 2011
- TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor MoleculesMolecular Pharmacology, 2011
- Production of Proinflammatory Cytokines and Chemokines During Neuroinflammation: Novel Roles for Estrogen Receptors α and βEndocrinology, 2010
- Glyburide inhibits the Cryopyrin/Nalp3 inflammasomeJournal of Cell Biology, 2009
- A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brainJournal of Cellular and Molecular Medicine, 2009
- P2X7 Receptor Differentially Couples to Distinct Release Pathways for IL-1β in Mouse MacrophageThe Journal of Immunology, 2008
- Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer diseaseJournal of Cellular Physiology, 2006